Wiley and IQVIA Release Cross-Sector Report on AI’s Promise and Pressure Points Across Healthcare Value Chain

Key Terms

ai technical

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

ai agents technical

AI agents are computer programs designed to perform tasks or make decisions automatically, often by learning from data and adapting to new information. They act like virtual assistants or robots that can handle complex activities without human intervention, which can help businesses and individuals save time and improve efficiency. For investors, AI agents matter because they can enhance decision-making and automate processes that influence markets and financial outcomes.

real-world data medical

Real-world data consists of information collected from everyday sources outside of controlled experiments or official reports, such as patient records, insurance claims, or wearable device readings. For investors, it provides a more complete picture of how products and services perform in actual use, helping them make better-informed decisions based on how things work in real life rather than just in theory or controlled settings.

real-world evidence medical

Real-world evidence is information gathered from everyday sources like patient records, insurance claims, or everyday experiences, rather than controlled experiments or clinical trials. It helps investors understand how products or policies perform in real life, providing a more complete picture of their effectiveness and value beyond official tests. This type of evidence can influence decision-making by offering insights based on actual, everyday outcomes.

clinical guidelines medical

Clinical guidelines are systematically developed recommendations from medical experts that outline the best ways to diagnose, treat, and manage specific health conditions; think of them as a trusted recipe or roadmap for doctors to follow. Investors care because these guidelines shape which tests, drugs, and devices become standard practice, driving demand, pricing, and insurance coverage — changes that can significantly affect a healthcare company's revenue and market value.

trial design medical

A trial design is the detailed plan for how a clinical study will test a drug, device or therapy — who joins, how people are assigned to treatments, what outcomes are measured, and how long the study runs. Like a blueprint for a building or a recipe for a dish, the design determines how believable and useful the results will be, so investors watch it closely because it shapes the chance of regulatory approval, costs, timelines and commercial prospects.

value chain technical

A value chain is the sequence of activities a company performs to create and deliver a product or service, from sourcing materials and manufacturing to distribution, sales and after‑sales support. For investors it reveals where costs, bottlenecks and competitive advantages live—think of it like a relay race where each handoff affects speed, quality and profit potential, so small improvements or disruptions can change a company’s returns.

peer review technical

Peer review is the process where independent experts evaluate a study, report or claim to check its methods, results and conclusions before it is accepted or published. For investors, peer review matters because it raises the credibility of scientific or technical claims—like a referee confirming the rules were followed—reducing the chance that decisions are based on flawed data and helping assess product, regulatory or market risks more reliably.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Insights drawn from executive Summit hosted by Wiley and IQVIA with leaders from pharma, academia, health systems, technology companies and more

HOBOKEN, N.J.--(BUSINESS WIRE)-- Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and learned societies.

The report summarizes insights from The Summit — an invitation-only, two-day working session co-hosted by Wiley and IQVIA in May 2026. The session opened with a forward-looking perspective on AI and organizational change from Ethan Mollick, Wharton professor, NYT bestselling author of Co-Intelligence, and the forthcoming Co-Existence (October 2026), which set the tone for the dynamic days of discussion. Participants included senior leaders from organizations such as Novo Nordisk, Microsoft, Amazon, Salesforce, American Association for the Advancement of Science (AAAS), American Heart Association, JAMA Network, Johns Hopkins University, University of Michigan, Mapúa University, South Dakota State University, American Society of Mechanical Engineers (ASME), BMJ Group, Japan Advanced Institute of Science and Technology, Queen Mary Intellectual Property Research Institute and Turbine.

A key focus of the report is the gap between AI's technical capability and the health system's ability to absorb it. AI is accelerating every stage of the journey from scientific discovery to patient benefit — but acceleration at one stage can create fracture at the next. Examining each stage of the science-to-patient value chain, participants identified five high-potential directions for the ecosystem:

• Decision-first discovery: Embracing AI for large-scale exploration to support wet lab target identification and validation.
• Structured negative data: Sharing vetted failed experiments to avoid unnecessary repetition.
• AI agents for patients: Deploying patient-facing AI to help them navigate health systems.
• Curated aggregation: Combining the scholarly record and real-world data as a trusted alternative to general-purpose AI search.
• Continuous learning loop: Feeding real-world evidence back into trial design, clinical guidelines and upstream research.

“For AI to deliver its full promise in healthcare and science, all parts of the system must be engaged. AI has vastly increased the speed at which we can resolve molecular identities and surface new candidates — but if the publishing model, clinical development infrastructure and real-world adoption don’t keep pace, those discoveries won’t reach patients as quickly as they should,” said Armughan Rafat, Wiley SVP, Chief AI & Data Analytics Officer. “That’s the conversation Wiley and IQVIA have convened. We didn’t set out to produce consensus, but rather to surface an honest diagnosis.”

"AI is already reshaping every stage of the healthcare value chain, but the real opportunity lies in connecting those stages into a continuous learning system. What emerged from The Summit is a clear need to move beyond isolated innovation toward integrated evidence ecosystems – where clinical research, real-world data and advanced analytics work in unison. By closing the loop between discovery, development and real-world outcomes, we can accelerate not just insight generation, but meaningful impact for patients," said Rob Kotchie, IQVIA President, Real World Evidence & Clinical Technology Solutions.

The report is also candid about identifying existing structural limits. A consistent finding across every stage of the value chain is that incentives are an impediment: the system rewards behaviors that don’t always optimize for science, patients or long-term progress. Addressing such misalignment requires collaboration across actors and structural change.

Scientific Discovery & AI: The Science-to-Patient Journey is available now at this link. The report maps the findings from The Summit across four stages of the science-to-patient value chain: Discovery & Early Research, Clinical Development & Evidence Generation, Validation & Dissemination and Real-World Adoption & Patient Impact.

Together, Wiley and IQVIA span the full value chain — from evidence creation and peer review through real-world clinical application — and are strongly positioned to connect the stakeholders who need to be in conversation.

About Wiley

Wiley (NYSE: WLY) is a global leader in authoritative content and research intelligence for the advancement of scientific discovery, innovation, and learning. With more than 200 years at the center of the scholarly ecosystem, Wiley combines trusted publishing heritage with AI-powered platforms to transform how knowledge is discovered, accessed, and applied. From individual researchers and students to Fortune 500 R&D teams, Wiley enables the transformation of scientific breakthroughs into real-world impact. From knowledge to impact—Wiley is redefining what's possible in science and learning. Visit us at Wiley.com and Investors.Wiley.com. Follow us on Facebook, X, LinkedIn and Instagram.

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI^®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

Category: All Corporate News

View source version on businesswire.com: https://www.businesswire.com/news/home/20260615344569/en/

Media Contact — Wiley: Geena De Rose / gderose@wiley.com
Media Contact — IQVIA: Alissa Maupin / alissa.maupin1@iqvia.com

Source: John Wiley and Sons